# Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

> **NCT00976755** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 37 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT00976755
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-14
- **Primary completion:** 2012-11-29
- **Final completion:** 2019-08-08
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976755, "Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00976755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*